Meeting
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
Authors
Frederick Lundry Locke
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Frederick Lundry Locke , Nancy L. Bartlett , Caron A. Jacobson , Olalekan O. Oluwole , Javier Munoz , Lazaros J. Lekakis , Max S. Topp , Irit Avivi , Jenny J. Kim , Rong Chu , Lianqing Zheng , John M. Rossi , Adrian Bot , Sattva Swarup Neelapu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02348216
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8012)
DOI
10.1200/JCO.2020.38.15_suppl.8012
Abstract #
8012
Poster Bd #
345
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
First Author: Frederick Lundry Locke
Poster
2019 ASCO Annual Meeting
Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL).
First Author: Sattva Swarup Neelapu
Poster
2019 ASCO Annual Meeting
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.
First Author: Jay Y. Spiegel
Poster
2019 ASCO Annual Meeting
ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL).
First Author: Sattva Swarup Neelapu